Ocular Surface Ion Transport and Dry Eye Disease
Purpose of Review To review the role of ocular surface epithelial (corneal and conjunctival) ion transporters in the pathogenesis and treatment of dry eye disease (DED). Recent Findings Currently, anti-inflammatory agents are the mainstay of DED treatment, though there are several agents in development that target ion transport proteins on the ocular surface, acting by pro-secretory or anti-absorptive mechanisms to increase the tear fluid film volume. Activation or inhibition of selected ion transporters can alter tear fluid osmolality, driving water transport onto the ocular surface via osmosis. Several ion transporters have been proposed as potential therapeutic targets for DED, including the cystic fibrosis transmembrane conductance regulator (CFTR), calcium-activated chloride channels (CaCCs), and the epithelial sodium channel (ENaC). Summary Ocular surface epithelial cell ion transporters are promising targets for pro-secretory and anti-absorptive therapies of DED..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Current ophthalmology reports - 10(2022), 4 vom: 20. Okt., Seite 188-197 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lindgren, Ethan S. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Conjunctiva |
|---|
| Anmerkungen: |
© The Author(s) 2022 |
|---|
| doi: |
10.1007/s40135-022-00295-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR048825301 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR048825301 | ||
| 003 | DE-627 | ||
| 005 | 20230519110903.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221207s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40135-022-00295-3 |2 doi | |
| 035 | |a (DE-627)SPR048825301 | ||
| 035 | |a (SPR)s40135-022-00295-3-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lindgren, Ethan S. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ocular Surface Ion Transport and Dry Eye Disease |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2022 | ||
| 520 | |a Purpose of Review To review the role of ocular surface epithelial (corneal and conjunctival) ion transporters in the pathogenesis and treatment of dry eye disease (DED). Recent Findings Currently, anti-inflammatory agents are the mainstay of DED treatment, though there are several agents in development that target ion transport proteins on the ocular surface, acting by pro-secretory or anti-absorptive mechanisms to increase the tear fluid film volume. Activation or inhibition of selected ion transporters can alter tear fluid osmolality, driving water transport onto the ocular surface via osmosis. Several ion transporters have been proposed as potential therapeutic targets for DED, including the cystic fibrosis transmembrane conductance regulator (CFTR), calcium-activated chloride channels (CaCCs), and the epithelial sodium channel (ENaC). Summary Ocular surface epithelial cell ion transporters are promising targets for pro-secretory and anti-absorptive therapies of DED. | ||
| 650 | 4 | |a Dry eye disease |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Ion transport |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Ocular surface electrophysiology |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Ocular surface epithelium |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cornea |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Conjunctiva |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Cil, Onur |4 aut | |
| 700 | 1 | |a Verkman, Alan S. |4 aut | |
| 700 | 1 | |a Pasricha, Neel D. |0 (orcid)0000-0002-2327-5221 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current ophthalmology reports |d New York, NY : Springer, 2013 |g 10(2022), 4 vom: 20. Okt., Seite 188-197 |w (DE-627)SPR032898053 |w (DE-600)2737923-1 |x 2167-4868 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2022 |g number:4 |g day:20 |g month:10 |g pages:188-197 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40135-022-00295-3 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2022 |e 4 |b 20 |c 10 |h 188-197 | ||